TEMP-PREVENT试验:依替膦酸二钠治疗年轻成人弹性假黄瘤随机双盲安慰剂对照临床试验研究方案
TEMP-PREVENT是一项随机双盲安慰剂对照试验,在荷兰乌得勒支大学医学中心评估20 mg/kg周期性依替膦酸二钠对18至55岁弹性假黄瘤患者异位钙化的影响,主要终点为基线至24个月腿动脉和颈动脉虹吸部钙化体积变化,招募于2023年4月开始,结果预计2027年公布。
要点
- 依替膦酸二钠20 mg/kg周期性给药用于18至55岁弹性假黄瘤患者。
- 主要终点为低剂量平扫CT测量的腿动脉和颈动脉虹吸部钙化体积变化。
- 招募于2023年4月开始,结果预计2027年公布。
核心结论
- TEMP-PREVENT试验旨在评估依替膦酸二钠对年轻成人弹性假黄瘤患者异位钙化的效果。
研究设计与样本
- 随机、双盲、安慰剂对照临床试验,研究20 mg/kg周期性依替膦酸二钠对18至55岁弹性假黄瘤患者异位钙化的影响。
- 研究在荷兰乌得勒支大学医学中心开展,招募于2023年4月开始,结果预计2027年公布。
关键数值与推荐
- 主要终点为基线至24个月腿动脉和颈动脉虹吸部钙化体积变化,采用低剂量平扫计算机断层扫描测量。
- 次要终点包括皮肤科、眼科、血管、实验室、认知和生活质量结局/参数的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pseudoxanthoma elasticum (PXE) is a genetic disease with autosomal recessive inheritance, characterized by slowly progressive ectopic calcification in the elastic fibers of the skin, Bruch's membrane in the retina, and in the arteries. Etidronate was found to be effective in halting the progression of arterial calcification in an earlier trial, including middle-aged patients with PXE with manifest arterial disease. It is uncertain if there are similar effects in young adult patients with PXE. METHODS: The TEMP-PREVENT study is a randomized, double-blind, placebo-controlled clinical trial, investigating the effect of 20 mg/kg cyclical etidronate on ectopic calcification in PXE patients of ≥ 18 and ≤ 55 years. The study is conducted at the University Medical Center, Utrecht, the Netherlands. The primary endpoint is the change in arterial calcification volume between baseline and 24 months in the leg arteries and carotid siphons, as measured on low-dose unenhanced Computed Tomography. Secondary endpoints are changes in dermatological, ophthalmological, vascular, laboratory, cognitive and quality of life outcomes/parameters. Recruiting started in April 2023. Results are expected in 2027 and will be dispersed through peer-reviewed journals and international conferences. DISCUSSION: PXE is a rare genetic disease for which there is currently no registered treatment. The TEMP-PREVENT trial is set out to evaluate the effects of etidronate in young adult patients with PXE. TRIAL REGISTRATION: The trial is registered at the Dutch Central Committee on Research Involving Human Subjects (CCMO) (registration number: NL75350.041.21), European Union Clinical Trials Register (EudraCT number: 2021-000434-34), and at ClinicalTrials.gov (ID: NCT05832580, registration date 2023-04-14).
引用
- Harmsen IM, Haverkamp M, van den Beukel TC, et al. The TEMP-PREVENT trial: a study protocol for a randomized, double-blind, placebo-controlled clinical trial of etidronate for treatment in young adult patients with pseudoxanthoma elasticum. Trials. 2025. PMID: 41131563. doi:10.1186/s13063-025-09064-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。